Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04674033 · ClinicalTrials.gov registry record

The Sweet PEA Study: Effects of Diet During Pregnancy on Infant Growth and Development.

A clinical trial of Obesity, sponsored by University of Southern California.

Completed
Registry status
93
Enrollment target
1
Study location

NCT04674033: Completed study of Obesity, sponsored by University of Southern California.

NCT04674033 is a study of Obesity that has completed, run by University of Southern California. The registered enrollment target is 93 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04674033, a study of Obesity, has completed, sponsored by University of Southern California.

COMPLETED
Registry status
93 participants
Enrollment target
1
Study location

Study Summary

The purpose of the Sweet PEA Study is to determine whether diet during pregnancy has an effect on infant's growth, body composition, and brain development.

Primary Outcome

Infant length (cm) will be measured using an infant measure mat.

Conditions Studied

Study Locations (1)

California

  • Children's Hospital Los Angeles - Los Angeles

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2019-01-18
Est. Completion 2020-07-01
University of Southern California

617 total trials

What the finished NCT04674033 record still lists

NCT04674033 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 0 interventions.

NCT04674033 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04674033 about?

NCT04674033 is a clinical study titled "The Sweet PEA Study: Effects of Diet During Pregnancy on Infant Growth and Development.". The purpose of the Sweet PEA Study is to determine whether diet during pregnancy has an effect on infant's growth, body composition, and brain development.

What is the current status of trial NCT04674033?

This trial is currently completed. The enrollment target is 93 participants. The study started on 2019-01-18. Estimated completion is 2020-07-01.

What conditions does trial NCT04674033 study?

This clinical trial studies the following conditions: Obesity.

Who is sponsoring clinical trial NCT04674033?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04674033 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04674033's enrollment target sits among peer trials

93 514th of 1053 higher than 538 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04674033, the US trial registry maintained by the National Library of Medicine. NCT04674033 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.